Product development issues for PEGylated proteins

References

• Reinders J, Sickmann A. Modificomics: Posttranslational modifications beyond protein phosphorylation and glycosylation. Biomolec Engineer 2007;24:169–177.
   PubMedGoogle Scholar
• Sola RJ, Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci 2009;98:1223–1245.
   PubMed Web of Science ®Google Scholar
• Kang JS, DeLuca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs 2009;14:363–380.
   PubMed Web of Science ®Google Scholar
• Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv 2006;13:399–409.
   PubMed Web of Science ®Google Scholar
• Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, Smith D. PEGylated proteins: Evaluation of their safety in the absence of definitive metabolism studies. Drug Metabol Disposit 2007;35:9–16.
   PubMed Web of Science ®Google Scholar
• Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev 2002;54:531–545.
   PubMed Web of Science ®Google Scholar
• Harris JM, Martin NE, Modi M. Pegylation – a novel process for modifying pharmacokinetics. Clin Pharmacokin 2001;40:539–551.
   PubMed Web of Science ®Google Scholar
• Fishburn CS. The pharmacology or PEGylation: Balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008;97:4167–4183.
   PubMed Web of Science ®Google Scholar
• Jevsavar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol J 2010;5:113–128.
   PubMed Web of Science ®Google Scholar
• Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009;6:1–16.
   PubMed Web of Science ®Google Scholar
• Veronese FM, Mero A. The impact of PEGylation on biological therapies. Biodrugs 2008;22:315–329.
   PubMed Web of Science ®Google Scholar
• Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10:1451–1458.
   PubMed Web of Science ®Google Scholar
• Veronese FM. Peptide and protein PEGylation: A review of problems and solutions. Biomaterials 2001;22:405–417.
   PubMed Web of Science ®Google Scholar
• Katre NV. The conjugation of proteins with polyethylene-glycol and other polymers – altering properties of proteins to enhance their therapeutic potential. Adv Drug Deliv Rev 1993;10:91–114.
   Web of Science ®Google Scholar
• Delgado C, Francis GE, Fisher D. The uses and properties of peg-linked proteins. Crit Rev Therapeut Drug Carrier Syst 1992;9:249–304.
   PubMed Web of Science ®Google Scholar
• Ryan SM, Mantovani G, Wang XX, Haddleton DM, Brayden DJ. Advances in PEGylation of important biotech molecules: Delivery aspects. Expert Opin Drug Deliv 2008;5:371–383.
   PubMed Web of Science ®Google Scholar
• Pasut G, Veronese FM. Pegylation for improving the effectiveness of therapeutic biomolecules. Drugs Today 2009;45:687–695.
   PubMed Web of Science ®Google Scholar
• Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: An overview. Adv Drug Deliv Rev 2009;61:1177–1188.
   PubMed Web of Science ®Google Scholar
• Pasut G, Sergi M, Veronese FM. Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv Drug Deliv Rev 2008;60:69–78.
   PubMed Web of Science ®Google Scholar
• Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nature Rev: Drug Discov 2003;2:214–221.
   PubMed Web of Science ®Google Scholar
• Zapilsky S. Chemistry of polyethylene glycol conjugates with biologically active moleucles. Adv Drug Deliv Rev 1995;16:157–182.
   Web of Science ®Google Scholar
• Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci 2010;99:2557–2575.
   PubMed Web of Science ®Google Scholar
• Hamburger R, Azaz E, Donbrow M. Autoxidation of polyoxyethylenic nonionic surfactants and of polyethylene glycols. Pharmaceut Acta Helvet 1975;50:10–17.
   PubMedGoogle Scholar
• Mcginity JW, Patel TR, Naqvi AH, Hill JA. Implications of peroxide formation in lotion and ointment dosage forms containing polyethylene glycols. Drug Develop Communic 1976;2:505–519.
   Web of Science ®Google Scholar
• Johnson DM, Taylor WF. Degradation of fenprostalene in polyethylene glycol-400 solution. J Pharm Sci 1984;73:1414–1417.
   PubMed Web of Science ®Google Scholar
• Wasylaschuk WR, Harmon PA, Wagner G, Harman AB, Templeton AC, Xu H, Reed RA. Evaluation of hydroperoxides in common pharmaceutical excipients. J Pharm Sci 2007;96:106–116.
   PubMed Web of Science ®Google Scholar
• Bindra DS, Williams TD, Stella VJ. Degradation of O-6-benzylguanine in aqueous polyethylene-glycol-400 (Peg-400) solutions – concerns with formaldehyde in Peg-400. Pharmaceut Res 1994;11:1060–1064.
   PubMed Web of Science ®Google Scholar
• Nassar MN, Nesarikar VN, Lozano R, Parker WL, Huang YD, Palaniswamy V, Xu WW, Khaselev N. Influence of formaldehyde impurity in polysorbate 80 and PEG-300 on the stability of a parenteral formulation of BMS-204352: Identification and control of the degradation product. Pharm Dev Technol 2004;9:189–195.
   PubMed Web of Science ®Google Scholar
• Ellis G. Degradation of crystalline polyethylene glycol 6000 and its effect on assays for macroprolactin and other analytes. Clin Biochem 2006;39:1035–1040.
   PubMed Web of Science ®Google Scholar
• Huang TH, Garceau ME, Gao P. Liquid chromatographic determination of residual hydrogen peroxide in pharmaceutical excipients using platinum and wired enzyme electrodes. J Pharmaceut Biomed Analysis 2003;31:1203–1210.
   PubMed Web of Science ®Google Scholar
• Ruiz L, Reyes N, Duany L, Franco A, Aroche K, Rando EH. Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin. Int J Pharm 2003;264:57–72.
   PubMed Web of Science ®Google Scholar
• Gitlin G, Tsarbopoulos A, Patel ST, Sydor W, Pramanik BN, Jacobs S, Westreich L, Mittelman S, Bausch JN. Isolation and characterization of a monomethioninesulfoxide variant of interferon alpha-2b. Pharmaceut Res 1996;13:762–769.
   PubMed Web of Science ®Google Scholar
• Puz MJ, Johnson BA, Murphy BJ. Use of the antioxidant BHT in asymmetric membrane tablet coatings to stabilize the core to the acid catalyzed peroxide oxidation of a thioether drug. Pharm Dev Technol 2005;10:115–125.
   PubMed Web of Science ®Google Scholar
• Gaberc-Porekar V, Zore I, Podobnik B, Menart V. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Develop 2008;11:242–250.
   PubMed Web of Science ®Google Scholar
• Kawai F. Microbial degradation of polyethers. Appl Microbiol Biotechnol 2002;58:30–38.
   PubMed Web of Science ®Google Scholar
• Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J Pharm Pharmaceut Sci 2000;3:125–136.
   PubMed Web of Science ®Google Scholar
• Yamashita M, Tani A, Kawai F. A new ether-spitting enzyme found in Gram-positive polyethylene glycol 6000-utilizing bacterium, Pseudonocardia sp. strain K1. Appl Microbiol Biotechnol 2004;66:174–179.
   PubMed Web of Science ®Google Scholar
• Beranova M, Wasserbauer R, Vancurova D, Stifter M, Ocenaskova J, Mara M. Effect of cytochrome P-450 inhibition and stimulation on intensity of polyethylene degradation in microsomal fraction of mouse and rat livers. Biomaterials 1990;11:521–524.
   PubMed Web of Science ®Google Scholar
• Donbrow M, Azaz E, Pillersdorf A. Autoxidation of polysorbates. J Pharm Sci 1978;67:1676–1681.
   PubMed Web of Science ®Google Scholar
• Ha E, Wang W, Wang YJ. Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci 2002;91:2252–2264.
   PubMed Web of Science ®Google Scholar
• Kumar V, Kalonia DS. Removal of peroxides in polyethylene glycols by vacuum drying: Implications in the stability of biotech and pharmaceutical formulations. AAPS Pharmscitech 2006;7: article 62.
   Web of Science ®Google Scholar
• Seely JE, Buckel SD, Green PD, Richey CW. Making site-specific PEGylation work. Biopharm Int 2005;18:30+.
   Web of Science ®Google Scholar
• Monfardini C, Schiavon O, Caliceti P, Morpurgo M, Harris JM, Veronese FM. A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconj Chem 1995;6:62–69.
   PubMed Web of Science ®Google Scholar
• Fee CJ, Van Alstine JA. PEG-proteins: Reaction engineering and separation issues. Chem Engineer Sci 2006;61:924–939.
   Web of Science ®Google Scholar
• Fee CJ. Size comparison between proteins PEGylated with branched and linear Poly(Ethylene glycol) molecules. Biotechnol Bioengineer 2007;98:725–731.
   PubMed Web of Science ®Google Scholar
• Pasut G, Veronese FM. Polymer-drug conjugation, recent achievements and general strategies. Progress Polymer Sci 2007;32:933–961.
   Web of Science ®Google Scholar
• Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002;54:459–476.
   PubMed Web of Science ®Google Scholar
• Canalle LA, Lowik DWPM, van Hest JCM. Polypeptide-polymer bioconjugates. Chem Soc Rev 2010;39:329–353.
   PubMed Web of Science ®Google Scholar
• Herman S, Hooftman G, Schacht E. Poly(ethylene glycol) with reactive endgroups. 1. Modification of proteins. J Bioactive Compatible Polymers 1995;10:145–187.
   Web of Science ®Google Scholar
• Abuchowski A, Kazo GM, Verhoest CR, Vanes T, Kafkewitz D, Nucci ML, Viau AT, Davis FF. Cancer-therapy with chemically modified enzymes .1. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 1984;7:175–186.
   PubMedGoogle Scholar
• Harris JM, Kozlowski A. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functionalized derivatives thereof for biochemical applications. US Patent No. 5,572,662, 1997.
   Google Scholar
• Abuchowski A, Vanes T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum-albumin by covalent attachment of polyethylene-glycol. J Biolog Chem 1977;252:3578–3581.
   PubMed Web of Science ®Google Scholar
• Abuchowski A, McCoy JR, Palczuk NC, Vanes T, Davis FF. Effect of covalent attachment of polyethylene-glycol on immunogenicity and circulating life of bovine liver catalase. J Biolog Chem 1977;252:3582–3586.
   PubMed Web of Science ®Google Scholar
• Elling L, Kula MR. Immunoaffinity partitioning synthesis and use of polyethylene glycol-oxirane for coupling to bovine serum albumin and monoclonal antibodies. Biotechnol Appl Biochem 1991;13:354–362.
   PubMed Web of Science ®Google Scholar
• Greenwald RB, Martinez AJ. Cyclic imide thione activated polyalkylene oxides. 5,405,877, 1995.
   Google Scholar
• Harris JM, Sedaghat-Herati MR. Preparation and use of polyethylene glycol propionaldehyde. US Patent No. 5,252,714, 1993.
   Google Scholar
• Bentley MD, Harris JM. Poly(ethyelene glycol) aldehyde hydrates and related polymers and applications in modifying amines. US Patent No. 5,990,237, 1999.
   Google Scholar
• Delgado C, Patel JN, Francis GE, Fisher D. Coupling of poly(ethylene glycol) to albumin under very mild conditions by activation with tresyl chloride – characterization of the conjugate by partitioning in aqueous 2-phase systems. Biotechnol Appl Biochem 1990;12:119–128.
   PubMed Web of Science ®Google Scholar
• Zapilsky S. Active carbonates of polyalkylene oxides for modification of polypeptides. US Patent No. 5,122,614, 1992.
   Google Scholar
• Veronese FM, Largajolli R, Boccu E, Benassi CA, Schiavon O. Surface modification of proteins. Activation of monomethoxy-polyethylene glycols by phenylchloroformates and modification of ribonuclease and superoxide dismutase. Appl Biochem Biotechnol 1985;11:141–152.
   PubMed Web of Science ®Google Scholar
• Kaul G, Amiji M. Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharmaceut Res 2002;19:1061–1067.
   PubMed Web of Science ®Google Scholar
• Lee BK, Kwon JS, Kim HJ, Yamamoto S, Lee EK. Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: Process performance, characterization, and in vitro bioactivity. Bioconjug Chem 2007;18:1728–1734.
   PubMed Web of Science ®Google Scholar
• Miron T, Wilchek M. A simplified method for the preparation of succinimidyl carbonate polyethylene-glycol for coupling to proteins. Bioconjug Chem 1993;4:568–569.
   PubMed Web of Science ®Google Scholar
• Tan YY, Sun XH, Xu MX, An ZL, Tan XZ, Tan XY, Han QH, Miljkovic DA, Yang M, Hoffman RM. Polyethylene glycol conjugation of recombinant methioninase for cancer therapy. Protein Express Purificat 1998;12:45–52.
   PubMed Web of Science ®Google Scholar
• Davis FF, Van Es T, Palczuk NC. Non-immunogenic polypeptides. US Patent No. 4,179,337, 1979.
   Google Scholar
• Zapilsky S, Meno-Rudolph S. Hydrazide derivatives of poly(ethylene glycol) and their bioconjugates, in polyethylene glycol chemistry and biological applications. ACS Sympos Series 1997;680:318–341.
   Google Scholar
• Greenwald RB, Pendri A, Blikal D. Highly water soluble taxol derivatives: 7 –polyethylene glycol carbamates and carbonates. J Organic Chem 1995;60:331–336.
   Web of Science ®Google Scholar
• Dolence EK, Hu C-Z Tsang, R, Sanders CG, Osaki S. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces. US Patent No. 5.650,234, 1997.
   Google Scholar
• Freitas DdS Spencer, PJ, Vassao RC, Abrahao-Neto J. Biochemical and biopharmaceutical properties of PEGylated uricase. Int J Pharm 2010;387:215–222.
   PubMedGoogle Scholar
• Veronese FM, Mero A, Caboi F, Sergi M, Marongiu C, Pasutt G. Site-specific pegylation of G-CSF by reversible denaturation. Bioconj Chem 2007;18:1824–1830.
   PubMed Web of Science ®Google Scholar
• Morpurgo M, Veronese FM, Kachensky D, Harris JM. Preparation and characterization of poly(ethylene glycol) vinyl sulfone. Bioconj Chem 1996;7:363–368.
   PubMed Web of Science ®Google Scholar
• Woghiren C, Sharma B, Stein S. Protected thiol-polyethylene-glycol – a new activated polymer for reversible protein modification. Bioconj Chem 1993;4:314–318.
   PubMed Web of Science ®Google Scholar
• Goodson RJ, Katre NV. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Bio-Technology 1990;8:343–346.
   PubMed Web of Science ®Google Scholar
• Manjula BN, Tsai AG, Intaglietta M, Tsai C-H Ho, C, Smith PK, Perumalsamy K, Kamika ND, Friedman JM, Acharya SA. Conjugation of multiple copies of polyethylene glycol to hemoglobin facilitated through thiolation: Influence on hemoglobin structure and function. Protein J 2005;24:133–146.
   PubMed Web of Science ®Google Scholar
• Acharya SA, Freidman JM, Manjula BN, Intaglietta M, Tsai AG, Winslow RM, Malavalli A, Vandegriff KD, Smith PK. Enhanced molecular volume of conservatively pegylated Hb: (SP-PEG5K)6-HbA is non-hypertensive. Artif Cells, Blood Substit Biotechnol 2005;33:239–255.
   PubMed Web of Science ®Google Scholar
• Peleg-Shulmann T, Tsubery H, Mironchik M, Fridkin M, Schreiber G, Shecter Y. Reversible PEGylation: A novel technology to release native interferon α2 over a long period of time. J Medicinal Chem 2004;47:4897–4904.
   PubMed Web of Science ®Google Scholar
• Shechter Y, Mironchik M, Saul A, Gershonov E, Precido-Patt L, Sasson K, Tsubery H, Mester B, Kapitovsky A, Rubinaut S, Vachutinski Y, Fridkin G, Fridkin M. New technologies to prolong life-time of peptide and protein drugs in vivo. Int J Peptide Res Therapeut 2006;12:105–117.
   Google Scholar
• Garman AJ, Kalindjian SB. The preparation and properties of novel reversible polymer-protein conjugates – 2-omega-methoxypolyethylene (5000) glycoxymethylene-3-methylmaleyl conjugates of plasminogen activators. FEBS Lett 1987;223:361–365.
   PubMed Web of Science ®Google Scholar
• Roberts MJ, Harris JM. Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy. J Pharm Sci 1998;87:1440–1445.
   PubMed Web of Science ®Google Scholar
• Kirpotin D, Hong KL, Mullah N, Papahadjopoulos D, Zalipsky S. Liposomes with detachable polymer coating: Destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Letters 1996;388:115–118.
   PubMed Web of Science ®Google Scholar
• Greenwald RB, Choe YH, McGuire J, Conover CD. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 2003;55:217–250.
   PubMed Web of Science ®Google Scholar
• Zhao H, Yang K, Martinez A, Basu A, Chintala R, Liu HC, Janjua A, Wang ML, Filpula D. Linear and branched bicin linkers for releasable PEGylation of macromolecules: Controlled release in vivo and in vitro from mono- and multi-PEGylated proteins. Bioconj Chem 2006;17:341–351.
   PubMed Web of Science ®Google Scholar
• Shechter Y, Mironchik M, Rubinaut S, Tsubery H, Sasson K, Marcus Y, Fridkin M. Reversible pegylation of insulin facilitates its prolonged action in vivo. Eur J Pharmaceut Biopharmaceut 2008;70:19–28.
   PubMed Web of Science ®Google Scholar
• Fipula D, Zhao H. Releasable PEGylation of proteins with customized linkers. Adv Drug Deliv Rev 2008;60:29–49.
   PubMed Web of Science ®Google Scholar
• Balan S, Choi JW, Godwin A, Teo I, Laborde CM, Heidelberger S, Zloh M, Shaunak S, Brocchini S. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. Bioconj Chem 2007;18:61–76.
   PubMed Web of Science ®Google Scholar
• Shaunak S, Godwin A, Choi JW, Balan S, Pedone E, Vijayarangam D, Heidelberger S, Teo I, Zloh M, Brocchini S. Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nature Chem Biol 2006;2:312–313.
   PubMed Web of Science ®Google Scholar
• Brocchini S, Godwin A, Balan S, Choi SW, Zloh M, Shaunak S. Disulfide bridge based PEGylation of proteins. Adv Drug Deliv Rev 2008;60:3–12.
   PubMed Web of Science ®Google Scholar
• Hershfield MS, Chaffee S, Korojohnson L, Mary A, Smith AA, Short SA. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene-glycol. Proc Nat Acad Sci USA 1991;88:7185–7189.
   PubMed Web of Science ®Google Scholar
• He XH, Shaw PC, Tam SC. Reducing the immunogenicity and improving the in vivo activity of trichosantin by site-directed pegylation. Life Sci 1995;65:355–368.
   Google Scholar
• Lee S, McNemar C. Substantially pure histidine-linked protein polymer conjugates. US Patent No. 5,985,263, 1999.
   Google Scholar
• Shozen N, Iijima I, Hohsaka T. Site-specific incorporation of PEGylated amino acids into protein using non-natural amino acid mutagenesis. Bioorg Medicin Chem Lett 2009;19:4909–4911.
   PubMed Web of Science ®Google Scholar
• Deiters A, Schultz PG. In vivo incorporation of an alkyne into proteins in Escherichia coli. Bioorgan Medicin Chem Lett 2005;15:1521–1524.
   PubMed Web of Science ®Google Scholar
• Orsatti L, Veronese FM. A unusual coupling of poly(ethylene glycol) to tyrosine residues in epidermal growth factor. J Bioact Compat Polym 1999;14:429–436.
   Web of Science ®Google Scholar
• Gaertner HF, Puigserver AJ. Increased activity and stability of polyethylene glycol-modified trypsin. Enzyme Microb Technol 1992;14:150–155.
   PubMed Web of Science ®Google Scholar
• Salmaso S, Semenzato A, Bersani S, Mastrotto F, Scomparin A, Caliceti P. Site-selective protein glycation and PEGylation. Eur Polymer J 2008;44:1378–1389.
   Web of Science ®Google Scholar
• Sato H, Ikeda M, Suzuki K, Hirayama K. Site-specific modification of interleukin-2 by the combined use of genetic engineering techniques and transglutaminase. Biochemistry 1996;35:13072–13080.
   PubMed Web of Science ®Google Scholar
• Sato H. Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev 2002;54:487–504.
   PubMed Web of Science ®Google Scholar
• Fontana A, Spolaore B, Mero A, Veronese FM. Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv Drug Deliv Rev 2008;60:13–28.
   PubMed Web of Science ®Google Scholar
• Maullu C, Raimondo D, Caboi F, Giogetti A, Sergi M, Valentini M, Tonon G, Tramonto A. Site-directed enzymatic PEGylation of the human granulocyte colony-stimulating factor. FEBS J 2009;276:6741–6750.
   PubMed Web of Science ®Google Scholar
• DeFrees S, Wang ZG, Xing R, Scott AE, Wang J, Zopf D, Gouty DL, Sjoberg ER, Panneerselvam K, Brinkman-Van Der Linden ECM, Bayer RJ, Tarp MA, Clausen H. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 2006;16:833–843.
   PubMed Web of Science ®Google Scholar
• Graham ML. Pegaspargase: A review of clinical studies. Adv Drug Deliv Rev 2003;55:1293–1302.
   PubMed Web of Science ®Google Scholar
• Levy Y, Hershfield MS, Fernandezmejia C, Polmar SH, Scudiery D, Berger M, Sorensen RU. Adenosine-deaminase deficiency with late onset of recurrent infections response to treatment with polyethylene-glycol modified adenosine-deaminase. J Pediatrics 1988;113:312–317.
   PubMed Web of Science ®Google Scholar
• Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002;54:547–570.
   PubMed Web of Science ®Google Scholar
• Veronese FM, Sacca B, de Laureto PP, Sergi M, Caliceti P, Schiavon O, Orsolini P. New PEGs for peptisssde and protein modification, suitable for identification of the PEGylation site. Bioconj Chem 2001;12:62–70.
   PubMed Web of Science ®Google Scholar
• Tsui SM, Lam WM, Lam TL, Chong HC, So PK, Kwok SY, Arnold S, Cheng PNM, Wheatley DN, Lo WH, Leung YC. Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: Preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC). Cancer Cell Int 2009;9: article 9.
   PubMed Web of Science ®Google Scholar
• Caliceti P, Schiavon O, Veronese FM, Chaiken IM. Effects of monomethoxypoly(ethylene glycol) modification of ribonuclease on antibody recognition, substrate specificity and conformational stability. J Molec Recognit 1990, 3: 89–93.
   PubMedGoogle Scholar
• Chiu H-C Zapilsky, S, Kopeckova P, Kopecek J. Enzymatic activity of chymotrypsin and its poly(ethylene glycol) conjugates towards low and high molecular weight substrates. Bioconj Chem 1993;4:290–295.
   PubMed Web of Science ®Google Scholar
• Kinstler OB, Brems DN, Lauren SL, Paige AG, Hamburger JB, Treuheit MJ. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharmaceut Res 1996;13:996–1002.
   PubMed Web of Science ®Google Scholar
• Freitas DdS, Abrahao-Neto J. Biochemical and biophysical characterization of lysozyme modified by PEGylation. Int J Pharm 2010;392:111–117.
   PubMedGoogle Scholar
• Koumenis IL, Shahrokh Z, Leong S, Hsei V, Deforge L, Zapata G. Modulating pharmacokinetics of an anti-interleukin-8 F(ab′)(2) by amine-specific PEGylation with preserved bioactivity. Int J Pharm 2000;198:83–95.
   PubMed Web of Science ®Google Scholar
• Fishburn CS. The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008;97:4167–4183.
   PubMed Web of Science ®Google Scholar
• Foser S, Weyer K, Huber W, Certa U. Improved biological and transcriptional activity of monopegylated interferon-alpha-2a isomers. Pharmacogenom J 2003;3:312–319.
   PubMed Web of Science ®Google Scholar
• Foser S, Schacher A, Weyer KA, Brugger D, Dietel E, Marti S, Schreitmuller T. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Express Purificat 2003;30:78–87.
   PubMed Web of Science ®Google Scholar
• Clark R, Olson K, Fuh G, Marian M, Mortensen D, Teshima F, Chang S, Chu H, Mukku V, CanovaDavis E, Somer T, Cronin M, Winkler M, Wells JA. Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biolog Chem 1996;271:21969–21977.
   PubMed Web of Science ®Google Scholar
• Sahu RK, Nacharaju P, Manjula BN, Acharya SA. Induced plasma expander-like properties as a function of PEG chains on extension arm facilitated PEGylation of albumin: ‘mushroom to brush-like’ conformational transition of the PEG-albumin conjugate. Artific Cells, Blood Subst Biotechnol 2009;37:245–256.
   PubMed Web of Science ®Google Scholar
• Zhai YQ, Zhao YJ, Lei JD, Su ZG, Ma GH. Enhanced circulation half-life of site-specific PEGylated rhG-CSF: Optimization of PEG molecular weight. J Biotechnol 2009;142:259–266.
   PubMed Web of Science ®Google Scholar
• Na DH, Youn YS, Lee IB, Park EJ, Park CJ, Lee KC. Effect of molecular size of PEGylated recombinant human epidermal growth factor on the biological activity and stability in rat wound tissue. Pharm Dev Technol 2006;11:513–519.
   PubMed Web of Science ®Google Scholar
• Bowen S, Tare N, Inoue T, Yamasaki M, Okabe M, Horii I, Eliason JF. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Experim Hematol 1999;27:425–432.
   PubMed Web of Science ®Google Scholar
• Eliason JF, Greway A, Tare N, Inoue T, Bowen S, Dar M, Yamasaki M, Okabe M, Horii I. Extended activity in cynomolgus monkeys of a granulocyte colony-stimulating factor mutein conjugated with high molecular weight polyethylene glycol. Stem Cells 2000;18:40–45.
   PubMed Web of Science ®Google Scholar
• Esposito P, Barbero L, Caccia P, Caliceti P, D’Antonio M, Piquet G, Veronese FM. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev 2003;55:1279–1291.
   PubMed Web of Science ®Google Scholar
• Kinstler O, Molineux G, Treuheit M, Ladd D, Gegg C. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2002;54:477–485.
   PubMed Web of Science ®Google Scholar
• Gaertner HF, Offord RE. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconj Chem 1996;7:38–44.
   PubMed Web of Science ®Google Scholar
• Wetzel R, Halualani R, Stults JT, Quan CA General method for highly selective cross-linking of unprotected polypeptides via pH-controlled modification of N-terminal alpha-amino groups. Bioconj Chem 1990;1:114–122.
   PubMed Web of Science ®Google Scholar
• Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ. Therapeutic antibody fragments with prolonged in vivo half-lives. Nature Biotechnol 1999;17:780–783.
   PubMed Web of Science ®Google Scholar
• Wilchek M, Bayer EA. Labeling glycoconjugates with hydrazide reagents. Meth Enzymol 1987;138:429–442.
   PubMed Web of Science ®Google Scholar
• Wolfe CAC, Hage DS. Studies on the rate and control of antibody oxidation by periodate. Analyt Biochem 1995;231:123–130.
   PubMed Web of Science ®Google Scholar
• Krinner EM, Hepp J, Hoffmann P, Bruckmaier S, Petersen L, Petsch S, Parr L, Schuster I, Mangold S, Lorenczewski G, Lutterbuse P, Buziol S, Hochheim I, Volkland J, Molhoj M, Sriskandarajah M, Strasser M, Itin C, Wolf A, Basu A, Yang K, Filpula D, Sorensen P, Kufer P, Baeuerle P, Raum T. A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration. Protein Eng Des Sel 2006;19:461–470.
   PubMed Web of Science ®Google Scholar
• Li XQ, Lei JD, Su ZG, Ma GH. Comparison of bioactivities of monopegylated rhG-CSF with branched and linear mPEG. Process Biochem 2007;42:1625–1631.
   Web of Science ®Google Scholar
• Talpaz M, Rakhit A, Rittweger K, O’Brien S, Cortes J, Fettner S, Hooftman L, Kantarjian H. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res 2005;11:6247–6255.
   PubMed Web of Science ®Google Scholar
• Matsushima A, Nishumura H, Ashihara Y, Yakata Y, Inada Y. Modification of E. coli asparaginase with 2,3-bis(O-methoxypolyethylene glycol)-6-chloro-s-triazine (activated PEG2); disappearance of binding ability towards anti-serum and retention of enzymatic activity. Chem Lett 1980:773–776.
   Web of Science ®Google Scholar
• Veronese FM, Caliceti P, Schiavon O. Branched and linear poly(ethylene glycol): Influence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates. J Bioact Compatib Polym 1997;12:196–207.
   Web of Science ®Google Scholar
• Webster R, Xie R, Didier E, Finn R, Finnessy J, Edgington A, Walker D. PEGylation of somatotropin (recombinant human growth hormone): Impact on its clearance in humans. Xenobiotica 2008;38:1340–1351.
   PubMed Web of Science ®Google Scholar
• Seely JE, Richey CW. Use of ion-exchange chromatography and hydrophobic interaction chromatography in the preparation and recovery of polyethylene glycol-linked proteins. J Chromatogr A 2001;908:235–241.
   PubMed Web of Science ®Google Scholar
• Lecolley F, Tao L, Mantovani G, Durkin I, Lautru S, Haddleton DM. A new approach to bioconjugates for proteins and peptides (‘pegylation’) utilising living radical polymerisation. Chem Commun 2004;2026–2027.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Lecolley F, Tao L, Haddleton DM, Clerx J, Cornelissen J, Velonia K. Design and synthesis of N-maleimido-functionalized hydrophilic polymers via copper-mediated living radical polymerization: A suitable alternative to PEGylation chemistry. J Am Chem Soc 2005;127:2966–2973.
   PubMed Web of Science ®Google Scholar
• Sapra P, Zhao H, Mehlig M, Malaby J, Kraft P, Longley C, Greenberger LM, Horak LD. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a captothecin-11 refractory model. Clin Cancer Res 2008;14:1888–1896.
   PubMed Web of Science ®Google Scholar
• Mero A, Spolaore B, Veronese FM, Fontana A. Transglutaminase-mediated PEGylation of proteins: Direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG. Bioconj Chem 2009;20:384–389.
   PubMed Web of Science ®Google Scholar
• Berna M, Dalzoppo D, Pasut G, Manunta M, Izzo L, Jones AT, Duncan R, Veronese FM. Novel monodisperse PEG-dendrons as new tools for targeted drug delivery: Synthesis, characterization and cellular uptake. Biomacromolecules 2006;7:146–153.
   PubMed Web of Science ®Google Scholar
• Knauf MJ, Bell DP, Hirtzer P, Luo ZP, Young JD, Katre NV. Relationship of effective molecular-size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biolog Chem 1988;263:15064–15070.
   PubMed Web of Science ®Google Scholar
• Schaffer C, Critchfield F, Nair J. The absorption and excretion of a liquid polyethylene glycol. J Am Pharmaceut Assoc: Sci Ed 1950;39:340–344.
   Web of Science ®Google Scholar
• Nieforth KA, Nadeau R, Patel IH. Use of an indirect pharmacodynamic stimulation model of MW protein induction to compare in vivo activity of interferon-a2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Therapeut 1996;59:636–646.
   PubMed Web of Science ®Google Scholar
• Hu T, Li D, Manjula BN, Acharya SA. Autoxidation of the site-specifically PEGylated hemoglobins: Role of the PEG chains and the sites of PEGylation in the autoxidation. Biochemistry 2008;47:10981–10990.
   PubMed Web of Science ®Google Scholar
• Hooftman G, Herman S, Schacht E. Poly(ethylene glycol)s with reactive endgroups. 2. Practical consideration for the preparation of protein-PEG conjugates. J Bioact Compat Polym 1996;11:135–159.
   Web of Science ®Google Scholar
• Bailon P, Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharmaceut Sci Technol Today 1998;1:352–356.
   Google Scholar
• Berger H, Pizzo SV. Preparation of polyethylene-glycol tissue plasminogen-activator adducts that retain functional-activity – characteristics and behavior in 3 animal species. Blood 1988;71:1641–1647.
   PubMed Web of Science ®Google Scholar
• Busby TF, Ingham KC. Separation of macromolecules by ultrafiltration – removal of poly(ethylene glycol) from human-albumin. J Biochem Biophys Meth 1980;2:191–206.
   PubMedGoogle Scholar
• Hinds KD, Kim SW. Effects of PEG conjugation on insulin properties. Adv Drug Deliv Rev 2002;54:505–530.
   PubMed Web of Science ®Google Scholar
• Kim TH, Lee H, Park TG. PEGylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres. Biomaterials 2002;23:2311–2317.
   PubMed Web of Science ®Google Scholar
• Nijs M, Azarkan M, Smolders N, Vincentelli J, Vries GMP, Duchateau J, Looze Y. Preliminary characterization of bovine beta-lactoglobulin after its conjugation to polyethylene glycol. Biotechnol Bioengineer 1997;54:40–49.
   PubMed Web of Science ®Google Scholar
• Baran ET, Ozer N, Hasirci V. Solid-phase enzyme modifictaion via affinity chromatography. J Chromatogr B 2003;794:311–322.
   PubMed Web of Science ®Google Scholar
• Edwards CK, Martin SW, Seely J, Kinstler O, Buckel S, Bendele AM, Cosenza ME, Feige U, Kohno T. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv Drug Deliv Rev 2003;55:1315–1336.
   PubMed Web of Science ®Google Scholar
• Stoner MR, Fischer N, Nixon L, Buckel S, Benke M, Austin F, Randolph TW, Kendrick BS. Protein-solute interactions affect the outcome of ultrafiltration/diafiltration operations. J Pharm Sci 2004;93:2332–2342.
   PubMed Web of Science ®Google Scholar
• Hamidi M, Rafiei P, Azadi A. Designing PEGylated therapeutic molecules: Advantages in ADMET properties. Expert Opin Drug Discov 2008;3:1293–1307.
   PubMed Web of Science ®Google Scholar
• Hoyle PC. Polymer-modified proteins: Preclinical development and regulatory strategies. Adv Drug Deliv Rev 1991;6:219–233.
   Web of Science ®Google Scholar
• Monkarsh SP, Spence C, Porter JE, Palleroni A, Nalin C, Rosen P, Bailon P. Isolation of positional isomers of mono-poly(ethylene glycol)ylated interferon-a2a and the determination of their biochemical and biological characteristics. ACS Sympos Series 1997;680:207–216.
   Google Scholar
• Fee CJ. Size-exclusion reaction chromatography: A new technique for protein PEGylation. Biotechnol Bioengineer 2003;82:200–206.
   PubMed Web of Science ®Google Scholar
• Snider J, Neville C, Yuan LC, Bullock J. Characterization of the heterogeneity of polyethylene glycol-modified superoxide-dismutase by chromatographic and electrophoretic techniques. J Chromatography 1992;599:141–155.
   PubMed Web of Science ®Google Scholar
• McGoff P, Baziotis AC, Maskiewicz R. Analysis of polyethylene-glycol modified superoxide-dismutase by chromatographic, electrophoretic, light-scattering, chemical and enzymatic methods. Chem Pharmaceut Bull 1988;36:3079–3091.
   PubMed Web of Science ®Google Scholar
• Fee CJ, Van Alstine JM. Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. Bioconj Chem 2004;15:1304–1313.
   PubMed Web of Science ®Google Scholar
• Kendrick BS, Kerwin BA, Chang BS, Philo JS. Online size-exclusion high-performance liquid chromatography light scattering and differential refractometry methods to determine degree of polymer conjugation to proteins and protein-protein or protein-ligand association states. Analyt Biochem 2001;299:136–146.
   PubMed Web of Science ®Google Scholar
• Bedu-Addo F, Moreadith R, Advant SJ. Preformulation development of recombinant pegylated staphylokinase SY161 using statistical design. AAPS Pharmsci 2002; 4:1–13.
   Google Scholar
• Zhang M, Zhang Y, Zhu SY, Wu LF, Dou HZ, Yin CH. Synthesis and chromatographic separation of monomethoxypolyethylene glycol modified insulin. Separat Sci Technol 2007;42:789–801.
   Web of Science ®Google Scholar
• Ramon J, Saez V, Baez R, Aldana R, Hardy E. PEGylated interferon-alpha 2b: A branched 40K polyethylene glycol derivative. Pharmaceut Res 2005;22:1374–1386.
   PubMed Web of Science ®Google Scholar
• Brumeanu T-D Zaghouani, H, Bona C. Purification of antigenized immunoglobulins derivatized with monomethoxylpolyethylene glycol. J Chromatogr A 1995;696:219–225.
   PubMed Web of Science ®Google Scholar
• Pabst TM, Buckley JJ, Hunter AK. Comparison of strong anion-exchangers for the purification of a PEGylated protein. J Chromatogr A 2007;1147:172–182.
   PubMed Web of Science ®Google Scholar
• Yun Q, Yang RE, Chen T, Bi JX, Ma GH, Su ZG. Reproducible preparation and effective separation of PEGylated recombinant human granulocyte colony-stimulating factor with novel ‘PEG-pellet’ PEGylation mode and ion-exchange chromatography. J Biotechnol 2005;118:67–74.
   PubMed Web of Science ®Google Scholar
• Poole CF. The essence of chromatography. Amsterdam: Elsevier; 2003.
   Google Scholar
• Cisneros-Ruiz M, Mayolo-Deloisa K, Przybycien TM, Rito-Palomares M. Separation of PEGylated from unmodified ribonuclease A using sepharose media. Separat Purificat Technol 2009;65:105–109.
   Web of Science ®Google Scholar
• Park EJ, Lee KC, Na DH. Separation of positional isomers of mono-poly(ethylene glycol)-modified octreotides by reversed-phase high-performance liquid chromatography. J Chromatogr A 2009;1216:7793–7797.
   PubMed Web of Science ®Google Scholar
• Park EJ, Na DH. Optimization of octreotide PEGylation by monitoring with fast reversed-phase high-performance liquid chromatography. Analyt Biochem 2008;380:140–142.
   PubMed Web of Science ®Google Scholar
• Piedmonte DM, Treuheit MJ. Formulation of Neulasta (R) (pegfilgrastim). Adv Drug Deliv Rev 2008;60:50–58.
   PubMed Web of Science ®Google Scholar
• Nie YJ, Zhang X, Wang XC, Chen JH. Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin. Bioconj Chem 2006;17:995–999.
   PubMed Web of Science ®Google Scholar
• Schneiderheinze J, Walden Z, Dufield R, Demarest C. Rapid online proteolytic mapping of pEGylated rhGH for identity confirmation, quantitation of methionine oxidation and quantitation of unPEGylated N-terminus using HPLC with UV detection. J Chromatogr B 2009;877:4065–4070.
   PubMed Web of Science ®Google Scholar
• Kudlicki W, Odom OW, Kramer G, Hardesty B. Activation and release of enzymatically inactive, full-length rhodanese that is bound to ribosomes as peptidyl-transfer-Rna. J Biolog Chem 1994;269:16549–16553.
   PubMed Web of Science ®Google Scholar
• Jones MN. Interaction of sodium dodecyl sulfate with polyethylene oxide. J Colloid Interface Sci 1967;23:36–42.
   Web of Science ®Google Scholar
• Odom OW, Kudlicki W, Kramer G, Hardesty B. An effect of polyethylene glycol 8000 on protein mobility in sodium dodecyl sulfate-polyacrylamide gel electrophoresis and a method for eliminating this effect. Analyt Biochem 1997;245:249–252.
   PubMed Web of Science ®Google Scholar
• Kurfürst MM. Detection and molecular-weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl-sulfate polyacrylamide-gel electrophoresis. Analyt Biochem 1992;200:244–248.
   PubMed Web of Science ®Google Scholar
• Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconj Chem 2001;12:195–202.
   PubMed Web of Science ®Google Scholar
• Zheng CY, Ma GH, Su ZG. Native PAGE eliminates the problem of PEG-SDS interaction in SDS-PAGE and rovides an alternative to HPLC in 2 characterization of protein PEGylation. Electrophoresis 2007;28:2801–2807.
   PubMed Web of Science ®Google Scholar
• Hardy E, Ramon J, Saez V, Baez R, Tejeda Y, Ruiz A. Detection of PEGylated proteins in polyacrylamide gels by reverse staining with zinc and imidazole salts. Electrophoresis 2008;29:2363–2371.
   PubMed Web of Science ®Google Scholar
• Cunico RL, Gruhn V, Kresin L, Nitecki DE, Wiktorowicz JE. Characterization of polyethylene-glycol modified proteins using charge-reversed capillary electrophoresis. J Chromatography 1991;559:467–477.
   Web of Science ®Google Scholar
• Bullock J, Chowdhury S, Johnston D. Characterization of poly(ethylene glycol)-modified superoxide dismutase: Comparison of capillary electrophoresis and matrix-assisted laser desorption ionization mass spectrometry. Analyt Chem 1996;68:3258–3264.
   Web of Science ®Google Scholar
• Bullock J, Chowdhury S, Severdia A, Sweeney J, Johnston D, Pachla L. Comparison of results of various methods used to determine the extent of modification of methoxy polyethylene glycol 5000-modified bovine cupri-zinc superoxide dismutase. Analyt Biochem 1997;254:254–262.
   PubMed Web of Science ®Google Scholar
• Li WJ, Su ZG. Quantitatively investigating monomethoxypolyethylene glycol modification of protein by capillary electrophoresis. J Biochem Biophys Meth 2004;59:65–74.
   PubMedGoogle Scholar
• Na DH, Lee KC. Capillary electrophoretic characterization of PEGylated human parathyroid hormone with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Analyt Biochem 2004;331:322–328.
   PubMed Web of Science ®Google Scholar
• Na DH, Park EJ, Jo YW, Lee KC. Capillary electrophoretic separation of high-molecular-weight poly(ethylene glycol)-modified proteins. Analyt Biochem 2008;373:207–212.
   PubMed Web of Science ®Google Scholar
• Kraly J, Fazal MA, Schoenherr RM, Bonn R, Harwood MM, Turner E, Jones M, Dovichi NJ. Bioanalytical applications of capillary electrophoresis. Analyt Chem 2006;78:4097–4110.
   PubMed Web of Science ®Google Scholar
• Kostal V, Katzenmeyer J, Arriaga EA. Capillary electrophoresis in bioanalysis. Analyt Chem 2008;80:4533–4550.
   PubMed Web of Science ®Google Scholar
• Svergun DI, Ekstrom F, Vandegriff KD, Malavalli A, Baker DA, Nilsson C, Winslow RM. Solution structure of poly(ethylene) glycol-conjugated hemoglobin revealed by small-angle X-ray scattering: Implications for a new oxygen therapeutic. Biophys J 2008;94:173–181.
   PubMed Web of Science ®Google Scholar
• Lu YL, Harding SE, Turner A, Smith B, Athwal DS, Grossman JG, Davis KG, Rowe AJ. Effect of PEGylation on the solution conformation of antibody fragments. J Pharm Sci 2008;97:2062–2079.
   PubMed Web of Science ®Google Scholar
• Dhalluin C, Ross A, Leuthold LA, Foser S, Gsell B, Muller F, Senn H. Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha(2a) and its individual positional isomers. Bioconj Chem 2005;16:504–517.
   PubMed Web of Science ®Google Scholar
• Habeeb AFS. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Analyt Biochem 1966;14:328–336.
   PubMed Web of Science ®Google Scholar
• Treethammathurot B, Ovartlarnporn C, Wungsintaweekul J, Duncan R, Wiwattanapatapee R. Effect of PEG molecular weight and linking chemistry on the biological activity and thermal stability of PEGylated trypsin. Int J Pharm 2008;357:252–259.
   PubMedGoogle Scholar
• Lopez-Cruz JI, Viniegra-Gonzalez G, Hernandez-Arana A. Thermostability of native and pegylated Myceliophthora thermophila laccase in aqueous and mixed solvents. Bioconj Chem 2006;17:1093–1098.
   PubMed Web of Science ®Google Scholar
• Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70–77.
   PubMed Web of Science ®Google Scholar
• Slavica A, Dib I, Nidetzky B. Selective modification of surface-exposed thiol groups in Trigonopsis variabilis (D)-Amino acid oxidase using poly(ethylene glycol) maleimide and its effect on activity and stability of the enzyme. Biotechnol Bioengineer 2007;96:9–17.
   PubMed Web of Science ®Google Scholar
• Huang YB, Komatsu T, Wang RM, Nakagawa A, Tsuchida E. Poly(ethylene glycol)-conjugated human serum albumin including iron porphyrins: Surface modification improves the O-2-transporting ability. Bioconj Chem 2006;17:393–398.
   PubMed Web of Science ®Google Scholar
• Wang YS, Youngster S, Bausch J, Zhang RM, McNemar C, Wyss DF. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 2000;39:10634–10640.
   PubMed Web of Science ®Google Scholar
• Heller MC, Carpenter JF, Randolph TW. Conformational stability of lyophilized PEGylated proteins in a phase-separating system. J Pharm Sci 1999;88:58–64.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Martinez JA, Sola RJ, Castillo B, Cintron-Colon HR, Rivera-Rivera I, Barletta G, Griebenow K. Stabilization of alpha-chymotrypsin upon PEGylation correlates with reduced structural dynamics. Biotechnol Bioengineer 2008;101:1142–1149.
   PubMed Web of Science ®Google Scholar
• Mabrouk PA. Effect of pegylation on the structure and function of horse cytochrome c. Bioconj Chem 1994;5:236–241.
   PubMed Web of Science ®Google Scholar
• Tan HN, Yang SL, Feng Y, Liu CH, Cao JC, Mu GY, Wang FS. Characterization and secondary structure analysis of endostatin covalently modified by polyethylene glycol and low molecular weight heparin. J Biochem 2008;144:207–213.
   PubMed Web of Science ®Google Scholar
• Hu T, Prabhakaran M, Acharya SA, Manjula BN. Influence of the chemistry of conjugation of poly(ethylene glycol) to Hb on the oxygen-binding and solution properties of the PEG-Hb conjugate. Biochem J 2005;392:555–564.
   PubMed Web of Science ®Google Scholar
• Basu A, Yang K, Wang ML, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu DC, Zhang ZF, Hua J, Hsieh MC, Zhou J, Petti G, Li XG, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconj Chem 2006;17:618–630.
   PubMed Web of Science ®Google Scholar
• Na DH, Lee KC, DeLuca PP. PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics. Pharmaceut Res 2005;22:743–749.
   PubMed Web of Science ®Google Scholar
• Salmaso S, Bersani S, Scomparin A, Mastrotto F, Scherpfer R, Tonon G, Caliceti P. Tailored PEG for rh-G-CSF analogue site-specific conjugation. Bioconj Chem 2009;20:1179–1185.
   PubMed Web of Science ®Google Scholar
• Cindric M, Cepo T, Galic N, Bukvic-Krajacic M, Tomczyk N, Vissers JPC, Bindila L, Peter-Katalinic J. Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites. J Pharmaceut Biomed Analysis 2007;44:388–395.
   PubMed Web of Science ®Google Scholar
• Grace M, Youngster S, Gitlin G, Sydor W, Xie L, Westreich L, Jacobs S, Brassard D, Bausch J, Bordens R. Structural and biologic characterization of pegylated recombinant IFN-alpha 2b. J Interferon Cytokine Res 2001;21:1103–1115.
   PubMed Web of Science ®Google Scholar
• Wang Y-J Liu, Y-D, Chen J, Hao S-J Hu, T, Ma G-H Su, Z-G. Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli. Int J Pharm 2010;386:154–164.
   Google Scholar
• Yu PZ, Qin D, Qin GH, Fan B, Ma GH, Su ZG. PEGylation of rhIL-1RA increased its solution stability at room temperature. Process Biochem 2009;44:1340–1345.
   Web of Science ®Google Scholar
• Long DL, Doherty DH, Eisenberg SP, Smith DJ, Rosendahl MS, Christensen KR, Edwards DP, Chlipala EA, Cox GN. Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity. Experim Hematol 2006;34:697–704.
   PubMed Web of Science ®Google Scholar
• Johnson C, Royal M, Moreadith R, Bedu-Addo F, Advant S, Wan M, Conn G. Monitoring manufacturing process yields, purity and stability of structural variants of PEGylated staphylokinase mutant SY161 by quantitative reverse-phase chromatography. Biomed Chromatogr 2003;17:335–344.
   PubMed Web of Science ®Google Scholar
• Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharmaceut Res 1997;14:969–975.
   PubMed Web of Science ®Google Scholar
• Harris JM. Poly(ethylene glycol) chemistry: Biotechnical and biomedical applications. New York: Plenum Press; 1992.
   Google Scholar
• Tattini V Jr, Parra DF, Polakiewicz B, Pitombo RNM. Effect of lyophilization on the structure and phase changes of PEGYlated-bovine serum albumin. Int J Pharm 2005;304:124–134.
   PubMedGoogle Scholar
• Cabrales P, Tsai AG, Winslow RM, Intaglietta M. Extreme hemodilution with PEG-hemoglobin vs. PEG-albumin. Am J Physiol 2005:289:H2392–2400.
   PubMed Web of Science ®Google Scholar
• Humphreys DP, Heywood SP, Henry A, Ait-Lhadj L, Antoniw P, Palframan R, Greenslade KJ, Carrington B, Reeks DG, Bowering LC, West S, Brandt HA. Alternative antibody Fab′ fragment PEGylation strategies: Combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering. Protein Eng Des Sel 2007;20:227–234.
   PubMed Web of Science ®Google Scholar
• Roovers RC, van Dongen G, Henegouwen P. Nanobodies in therapeutic applications. Curr Opin Molec Therapeut 2007;9:327–335.
   PubMedGoogle Scholar
• Lee KC, Moon SC, Park MO, Lee JT, Na DH, Yoo SD, Lee HS, DeLuca PP. Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins. Pharmaceut Res 1999;16:813–818.
   PubMed Web of Science ®Google Scholar
• Na DH, Park MO, Choi SY, Kim YS, Lee SS, Yoo SD, Lee HS, Lee KC. Identification of the modifying sites of mono-PEGylated salmon calcitonins by capillary electrophoresis and MALDI-TOF mass spectrometry. J Chromatogr B-Analyt Technol Biomed Life Sci 2001;754:259–263.
   PubMed Web of Science ®Google Scholar
• Youn YS, Jung JY, Oh SH, Yoo SD, Lee KC. Improved intestinal delivery of salmon calcitonin by Lys(18)-amine specific PEGylation: Stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J Control Release 2006;114:334–342.
   PubMed Web of Science ®Google Scholar
• Tong Y, Zhong K, Tian H, Gao X, Xu X, Yin X, Yao W. Characterization of a monoPEG20000-Endostar. Int J Biolog Macromolec 2010;46:331–336.
   PubMed Web of Science ®Google Scholar
• Severs J, Samuels N, Teare J, Tollner A, Regan L. In: Characterization of PEGylated factor VIII molecules. American Society of Hematology Annual Meeting, 2006; Blood: 2006; p Abstract 4024.
   Google Scholar
• Tang L, Pan C, Atwal H, Nixon J, Barnett T, Murphy JE, Mei B, Fournel M. In: PEGYlation of Factor VIII reduced the inhibitory effects of human antibody inhibitors on the Factor VIII molecule. American Society of Hematology Annual Meeting, 2006; Blood: 2006; p Abstract 4017.
   Google Scholar
• Stigsnaes P, Frokjaer S, Bjerregaard S, van de Weert M, Kingshott P, Moeller EH. Characterisation and physical stability of PEGylated glucagon. Int J Pharm 2007;330:89–98.
   PubMedGoogle Scholar
• Youn YS, Lee KC. Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12). Bioconj Chem 2007;18:500–506.
   PubMed Web of Science ®Google Scholar
• Youn YS, Na DH, Yoo SD, Song SC, Lee KC. Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycol-modified growth hormone-releasing factor (1–29). J Chromatogr A 2004;1061:45–49.
   PubMed Web of Science ®Google Scholar
• Parkinson C, Scarlett JA, Trainer PJ. Pegvisomant in the treatment of acromegaly. Adv Drug Deliv Rev 2003;55:1303–1314.
   PubMed Web of Science ®Google Scholar
• Park EJ, Na DH, Lee KC. In vitro release study of mono-PEGylated growth hormone-releasing peptide-6 from PLGA microspheres. Int J Pharm 2007;343:281–283.
   PubMed Web of Science ®Google Scholar
• Suo X, Zheng C, Yu P, Lu X, Ma G, Su Z. Solid phase pegylation of hemoglobin. Artif Cells, Blood Subst Biotechnol 2009;37:147–155.
   PubMed Web of Science ®Google Scholar
• Lui FE, Kluger R. Enhancing nitrite reductase activity of modified hemoglobin: Bis-tetramers and their PEGylated derivatives. Biochemistry 2009;48:11912–11919.
   PubMed Web of Science ®Google Scholar
• Diesen D, Stamler JS. S-nitrosylation and PEGylation of hemoglobin: Toward a blood substitute that recapitulates blood. J Molec Cellular Cardiol 2007;42:921–923.
   PubMed Web of Science ®Google Scholar
• Cabrales P, Kanika ND, Manjula BN, Tsai AG, Acharya SA, Intaglietta M. Microvascular PO2 during extreme hemodilution with hemoglobin site specifically PEGylated at Cys-93(b) in hamster window chamber. Am J Physiol 2004;287:H1609–1617.
   Google Scholar
• Yang K, Basu A, Wang M, Chintala R, Hsieh M-C Liu, S, Hua J, Zhang Z, Zhou J, Li M, Phyu H, Petti G, Mendez M, Janjua H, Peng P, Longley C, Borowski V, Mehlig M, Filpula D. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Engineer 2003;16:761–770.
   PubMedGoogle Scholar
• Zhao J, Li XQ, Xiu ZL. Specific-site PEGylation of hirudin on ion-exchange column and theoretical prediction and analysis of modified sites by molecular dynamics simulation. Chem J Chin Univ-Chin 2009;30:1410–1416.
   Web of Science ®Google Scholar
• Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation. Bioconj Chem 2005;16:200–207.
   PubMed Web of Science ®Google Scholar
• Jo YW, Youn YS, Lee SH, Kim BM, Kang SH, Yoo M, Choi EC, Lee KC. Long-acting interferon-alpha-2a modified with a trimer-structured polyethylene glycol: Preparation, in vitro bioactivity, in vivo stability and pharmacokinetics. Int J Pharm 2006;309:87–93.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Modi MW, Pedder S. Use of peginterferon alfa-2a (40 kD) (Pegasys) for the treatment of hepatitis C. Adv Drug Deliv Rev 2002;54:571–586.
   PubMed Web of Science ®Google Scholar
• Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen DY, Hess DM, Chen LQ, Grant D, Whitty A, Gill A, Lindner DJ, Pepinsky RB. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconj Chem 2006;17:179–188.
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Tsunoda S, Kamada H. PEGylation of interleukin-6 effectively increases its thrombopoietic potency. Thrombosis Haemostasis 1997;77:168–173.
   PubMed Web of Science ®Google Scholar
• Huang Z, Ni CY, Chu YH, Wang SS, Yang SL, Wu XP, Wang XJ, Li XK, Feng WK, Lin SQ. Chemical modification of recombinant human keratinocyte growth factor 2 with polyethylene glycol improves biostability and reduces animal immunogenicity. J Biotechnol 2009;142:242–249.
   PubMed Web of Science ®Google Scholar
• Moreadith RW, Collen D. Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thromolytic treatment of patients with acute myocardial infarction. Adv Drug Deliv Rev 2003;55:1337–1345.
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Kihira T, Tsunoda S. Molecular design of hybrid tumour necrosis factor alfa with polyethylene glycol increases its anti-tumour potency. Br J Cancer 1995;71:963–968.
   PubMed Web of Science ®Google Scholar
• Schiavon O, Caliceti P, Ferruti P, Veronese FM. Therapeutic proteins: A comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine). Farmaco 2000;55:264–269.
   PubMedGoogle Scholar
• Sherman MR, Saifer MGP, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008;60:59–68.
   PubMed Web of Science ®Google Scholar